期刊
ATHEROSCLEROSIS
卷 245, 期 -, 页码 161-170出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2015.12.018
关键词
-
资金
- UK Medical Research Council
- British Heart Foundation
- Cancer Research UK
- MRC [MC_U137686853] Funding Source: UKRI
- Medical Research Council [MC_U137686853] Funding Source: researchfish
Cardiovascular disease (CVD) is the leading cause of mortality worldwide. Observational data indicate that low-density lipoprotein cholesterol (LDL-C) levels are strongly positively associated with the risk of coronary heart disease (CHD) whilst the level of high-density lipoprotein cholesterol (HDL-C) is strongly inversely associated, with additional associations being observed for other lipid parameters such as triglycerides, apolipoproteins and lipoprotein(a) (Lp(a)). This has led to an interest in the development of a range of lipid intervention therapies. The most widely used of these interventions are statins, but even with intensive statin therapy some groups of patients remain at significant residual cardiovascular (CV) risk. In addition, some people are intolerant of statin therapy. In these circumstances, additional therapeutic agents may be needed. This review considers the evidence behind and the pros and cons of such additional agents. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据